



Virtual-committee members only

Members:	ATTENDANCE
Chris Mares, PhD	Chair, Scientist
David Smyth, PhD	Scientist
Donna Lehman, PhD	Scientist
George Perry, PhD	External Member
Others:	
Rani Muthukrishnan, PhD	Executive Director of Research Compliance
Mary Jo Bilicek, M.S.	Research Compliance Coordinator

MINUTES:

1. Attendee count

- 1.1 4 in attendance, quorum attained.
- 1.2 The meeting was called to order by the Chair at 2:02pm
- 1.3 The Chair established all members acknowledged and agreed to the Confidentiality Statement.
- 1.4 The Chair asked members to confirm no conflict of interest (COI).

4. Old Business

Business containing work covered by *NIH Guidelines*

4.4 2025-07 *Biochemical studies on recombinant iron transport proteins from different bacteria*

Protocol revisions from the November meeting were presented. The committee discussed the risk and need regarding proposed use of sonication method. Could bath with tubes/enclosures be used to minimize aerosolization? Transportation needs to be clarified. Is it just within the main lab or between buildings? Ensure lab safety manual and shared space form are submitted. The portable BSC and the lab need to be inspected. Clarify the source of the vector. An MTA might be required.

Motion to table protocol 2025-07 pending revisions/clarifications from the PI. D. Smyth and seconded by D. Lehman

Approved 4, abstained 0, rejected 0

5. New Business

Business containing work covered by *NIH Guidelines*

5.1 2025-08 *Evaluation of Nanoparticle Therapeutics in 2D and 3D Cell Culture Models of Breast and Pancreatic Cancer*

Chair provided an overview of the protocol. This project explores new ways to treat breast and pancreatic cancers by using nanoparticles to deliver medicines directly to cancer cells. The PI will test these particles in both regular cell cultures and 3D models that better mimic real tumors, with the goal of making treatments more effective and reducing side effects.

Suggestion was made to store cells in liquid nitrogen opposed to -80 freezers. The committee would like more details regarding the storage and handling of cell lines. PI must provide lab safety manual and lab must be inspected. PI needs to confirm that



TEXAS A&M UNIVERSITY- SAN ANTONIO

sonification and homogenization will be done in the hood to avoid aspiration. All training must be completed prior to approval. Clarify how nanoparticles will be introduced into cells. Will imaging be used? The committee requested the PI to explain the risks vs benefits. The committee wants clarification regarding how the proposed techniques will yield results. It's not clear how cells will be maintained. If future publication is considered, a clear tracking mechanism with passage numbers needs to be presented.

**Motion to table protocol 2025-08 pending revisions/clarifications from the PI. C. Mares and seconded by D. Smyth
Approved 4, abstained 0, rejected 0**

Business NOT containing work covered by *NIH Guidelines* discussed

6. Next Meeting:
February 18th

**Motion to adjourn meeting by G. Perry and seconded by D. Smyth
Approved 4, abstained 0, rejected 0
Meeting adjourned at 3:05pm**